

Title (en)

Use of bi-and trispecific antibodies for inducing tumor immunity

Title (de)

Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumورimmunität

Title (fr)

Utilisation des anticorps bi- et trispécifiques pour induire une immunité antitumorale

Publication

EP 0826696 B1 20020529 (DE)

Application

EP 97115190 A 19970902

Priority

- DE 19635743 A 19960903
- DE 19648976 A 19961126
- DE 19710497 A 19970313

Abstract (en)

[origin: EP0826696A1] Use of an intact bispecific or tri-specific antibody to prepare a medicament for inducing tumour immunity in humans and animals is claimed (an intact bispecific antibody is a hybrid antibody comprising two different Fab fragments and an Fc fragment; the term "intact tri-specific antibody" is not defined). The intact bispecific or tri-specific antibody must: (a) bind to a T cell and mediate a first activation signal therein, (b) bind to tumour-associated antigens on a tumour cell, (c) bind through its Fc fragment (in the case of bispecific antibodies) or through "a third specificity" (in the case of tri-specific antibodies) to the Fc receptors of Fc-receptor positive cells and (d) activate the Fc-receptor positive cells by binding to the Fc receptors, whereby expression of cytokines and/or co-stimulatory antigens is initiated or enhanced, the cytokines and/or co-stimulatory antigens transmitting to the T cells a second activation signal necessary for physiological activation of the T cells, this activation being manifested in up-regulation of activation markers, destruction of tumour cells and/or proliferation of the T cells.

IPC 1-7

C07K 16/46; **A61K 39/395**

IPC 8 full level

C12N 15/02 (2006.01); **A61K 39/395** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01); **C07K 16/30** (2006.01); **C07K 16/46** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP US)

A61P 35/00 (2017.12 - EP); **C07K 16/2809** (2013.01 - EP US); **C07K 16/30** (2013.01 - EP US); **C07K 16/468** (2013.01 - EP US); **A61K 38/00** (2013.01 - EP US); **C07K 2319/00** (2013.01 - EP US)

Citation (examination)

- J. of Hematotherapy, Bd. 4, 1995, Seiten 433-437
- Cancer Immunol. Immunother., Bd. 40, 1995, Seiten: 390-396

Cited by

CN102481367A; WO0018806A1; WO03011337A1; JP2014522644A; EP4252772A3; WO2013005194A3; US9631031B2; US10815310B2; US11945879B2

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB IT LI NL SE

DOCDB simple family (publication)

EP 0826696 A1 19980304; **EP 0826696 B1 20020529**; AT E218143 T1 20020615; DK 0826696 T3 20020923; ES 2176574 T3 20021201; JP 3442265 B2 20030902; JP H10182487 A 19980707; US 2002051780 A1 20020502; US 6551592 B2 20030422

DOCDB simple family (application)

EP 97115190 A 19970902; AT 97115190 T 19970902; DK 97115190 T 19970902; ES 97115190 T 19970902; JP 23874697 A 19970903; US 92385297 A 19970903